Seres Therapeutics (MCRB) Return on Assets (2016 - 2025)
Historic Return on Assets for Seres Therapeutics (MCRB) over the last 11 years, with Q2 2025 value amounting to 0.91%.
- Seres Therapeutics' Return on Assets rose 9900.0% to 0.91% in Q2 2025 from the same period last year, while for Jun 2025 it was 0.91%, marking a year-over-year increase of 9900.0%. This contributed to the annual value of 0.51% for FY2024, which is 2900.0% up from last year.
- Per Seres Therapeutics' latest filing, its Return on Assets stood at 0.91% for Q2 2025, which was up 9900.0% from 0.88% recorded in Q1 2025.
- Seres Therapeutics' Return on Assets' 5-year high stood at 0.91% during Q2 2025, with a 5-year trough of 0.79% in Q3 2022.
- Its 5-year average for Return on Assets is 0.06%, with a median of 0.14% in 2023.
- Per our database at Business Quant, Seres Therapeutics' Return on Assets tumbled by -6900bps in 2022 and then soared by 9900bps in 2025.
- Seres Therapeutics' Return on Assets (Quarter) stood at 0.17% in 2021, then crashed by -222bps to 0.55% in 2022, then skyrocketed by 82bps to 0.1% in 2023, then surged by 880bps to 0.79% in 2024, then rose by 15bps to 0.91% in 2025.
- Its Return on Assets stands at 0.91% for Q2 2025, versus 0.88% for Q1 2025 and 0.79% for Q4 2024.